Sulfopropanoic acid derivatives for treating neurodegenerative disorders: a patent spotlight

References

• WWW.Alz.org [internet]. Alzheimer's Association. New Alzheimer's association report reveals sharp increases in Alzheimer's prevalence, deaths, cost of care. [ cited 2018 May 30]. Available from: https://www.alz.org/news/2018/new_alzheimer_s_association_report_reveals_sharp_i#:~:text=An%20estimated%205.7%20million%20Americans,and%20older%20affected%20in%202018
   Google Scholar
• GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer's disease and other dementias, 1990 – 2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(1):88–106. doi:10.1016/S1474-4422(18)30403-4
   PubMed Web of Science ®Google Scholar
• Al-Horani RA. Steroid sulfatase inhibitors and sulfated C19 steroids for proteotoxicity-related diseases: a patent spotlight. Pharm Pat Anal. 2023;12(5):213–218. doi:10.4155/ppa-2023-0010
   PubMed Web of Science ®Google Scholar
• Al-Horani RA. Riluzole and its prodrugs for the treatment of Alzheimer's disease. Pharm Pat Anal. 2023;12(2):79–85. doi:10.4155/ppa-2023-0001
   PubMed Web of Science ®Google Scholar
• Salloway S, Sperling R, Fox NC, et al. Two phase III trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014;370(4):322–333. doi:10.1056/NEJMoa1304839
   PubMed Web of Science ®Google Scholar
• Sevigny J, Chiao P, Bussière T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature. 2016;537(7618):50–56. doi:10.1038/nature19323
   PubMed Web of Science ®Google Scholar
• Hampel H, O'Bryant SE, Castrillo JI, et al. PRECISION MEDICINE - the golden gate for detection, treatment and prevention of Alzheimer's disease. J Prev Alzheimers Dis. 2016;3(4):243–259. doi:10.14283/jpad.2016.112
   PubMedGoogle Scholar
• Esparza TJ, Zhao H, Cirrito JR, et al. Amyloid-β oligomerization in Alzheimer dementia versus high-pathology controls. Ann Neurol. 2013;73(1):104–119. doi:10.1002/ana.23748
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Serrano-Pozo A, Hori Y, et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide. J Neurosci. 2012;32(43):15181–15192. doi:10.1523/JNEUROSCI.1542-12.2012
   PubMed Web of Science ®Google Scholar
• Ono K, Yamada M. Low-n oligomers as therapeutic targets of Alzheimer's disease. J Neurochem. 2011;117(1):19–28. doi:10.1111/j.1471-4159.2011.07187.x
   PubMed Web of Science ®Google Scholar
• Townsend M, Shankar GM, Mehta T, et al. Effects of secreted oligomers of amyloid beta-protein on hippocampal synaptic plasticity: a potent role for trimers. J Physiol. 2006;572(Pt 2):477–492. doi:10.1113/jphysiol.2005.103754
   PubMed Web of Science ®Google Scholar
• Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci USA. 1998;95(11):6448–6453. doi:10.1073/pnas.95.11.6448
   PubMed Web of Science ®Google Scholar
• Usui K, Hulleman JD, Paulsson JF, Siegel SJ, Powers ET, Kelly JW. Site-specific modification of Alzheimer's peptides by cholesterol oxidation products enhances aggregation energetics and neurotoxicity. Proc Natl Acad Sci USA. 2009;106(44):18563–18568. doi:10.1073/pnas.0804758106
   PubMed Web of Science ®Google Scholar
• Gauthier S, Aisen PS, Ferris SH, et al. Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study. J Nutr Health Aging. 2009;13(6):550–557. doi:10.1007/s12603-009-0106-x
   PubMed Web of Science ®Google Scholar
• Saumier D, Duong A, Haine D, Garceau D, Sampalis J. Domain-specific cognitive effects of tramiprosate in patients with mild to moderate Alzheimer's disease: ADAS-cog subscale results from the Alphase Study. J Nutr Health Aging. 2009;13(9):808–812. doi:10.1007/s12603-009-0217-4
   PubMed Web of Science ®Google Scholar
• Aisen PS, Gauthier S, Ferris SH, et al. Tramiprosate in mild-to-moderate Alzheimer's disease - a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study). Arch Med Sci. 2011;7(1):102–111. doi:10.5114/aoms.2011.20612
   PubMed Web of Science ®Google Scholar
• Hey JA, Yu JY, Versavel M, et al. Clinical pharmacokinetics and safety of ALZ-801, a novel prodrug of tramiprosate in development for the treatment of Alzheimer's disease. Clin Pharmacokinet. 2018;57(3):315–333. doi:10.1007/s40262-017-0608-3
   PubMed Web of Science ®Google Scholar
• Kocis P, Tolar M, Yu J, et al. Elucidating the Aβ42 anti-aggregation mechanism of action of tramiprosate in Alzheimer's disease: integrating molecular analytical methods, pharmacokinetic and clinical data. CNS Drugs. 2017;31(6):495–509. doi:10.1007/s40263-017-0434-z
   PubMed Web of Science ®Google Scholar
• Abushakra S, Porsteinsson A, Scheltens P, et al. Clinical effects of tramiprosate in APOE4/4 homozygous patients with mild Alzheimer's disease suggest disease modification potential. J Prev Alzheimers Dis. 2017;4(3):149–156. doi:10.14283/jpad.2017.26
   PubMed Web of Science ®Google Scholar
• Pangman VC, Sloan J, Guse L. An examination of psychometric properties of the mini-mental state examination and the standardized mini-mental state examination: implications for clinical practice. Appl Nurs Res. 2000;13(4):209–213. doi:10.1053/apnr.2000.9231
   PubMed Web of Science ®Google Scholar
• Kocis P, Hey J, Tolar M. Sulfopropanoic acid derivatives for treating neurodegenerative disorders. WO 2020/028348 Al. Published: June 2, 2020. Available from: https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020028348
   Google Scholar
• Tolar M, Hey J, Power A, et al. Neurotoxic soluble amyloid oligomers drive Alzheimer's pathogenesis and represent a clinically validated target for slowing disease progression. Int J Mol Sci. 2021;22(12):6355. doi:10.3390/ijms22126355
   PubMed Web of Science ®Google Scholar
• Alzheon.com [internet]. Alzheon, Inc.; [ cited 2023 Dec 26]. Available from: https://alzheon.com/clinical-data/
   Google Scholar
• Meera P, Uusi-Oukari M, Lipshutz GS, et al. GABAA receptors as plausible molecular targets and mediators for taurine and homotaurine actions. Front Pharmacol. 2023;14:1271203. doi:10.3389/fphar.2023.1271203
   PubMed Web of Science ®Google Scholar
• Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015;16(6):358–372. doi:10.1038/nrn3880
   PubMed Web of Science ®Google Scholar
• Jorfi M, Maaser-Hecker A, Tanzi RE. The neuroimmune axis of Alzheimer's disease. Genome Med. 2023;15(1):6. doi:10.1186/s13073-023-01155-w
   PubMed Web of Science ®Google Scholar
• Gervais F, Paquette J, Morissette C, et al. Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging 2007;28(4):537–547. doi:10.1016/j.neurobiolaging.2006.02.015
   PubMed Web of Science ®Google Scholar
• Alzheon.com [internet]. Alzheon, Inc.; [ cited 2023 Dec 26]. Available from: https://alzheon.com/pipeline/alz-801-development/
   Google Scholar
• Manzano S, Agüera L, Aguilar M, Olazarán J. A review on tramiprosate (Homotaurine) in Alzheimer's disease and other neurocognitive disorders. Front Neurol. 2020;11:614. doi:10.3389/fneur.2020.00614
   PubMed Web of Science ®Google Scholar
• Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two randomized phase III studies of aducanumab in early Alzheimer's disease. J Prev Alzheimers Dis. 2022;9(2):197–210. doi:10.14283/jpad.2022.30
   PubMed Web of Science ®Google Scholar
• van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388(1):9–21. doi:10.1056/NEJMoa2212948
   PubMed Web of Science ®Google Scholar
• McGeer PL, McGeer EG. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol. 2013;126(4):479–497. doi:10.1007/s00401-013-1177-7
   PubMed Web of Science ®Google Scholar
• Tian J, Dang H, Wallner M, Olsen R, Kaufman DL. Homotaurine, a safe blood-brain barrier permeable GABAA-R-specific agonist, ameliorates disease in mouse models of multiple sclerosis. Sci Rep. 2018;8(1):16555. doi:10.1038/s41598-018-32733-3
   PubMedGoogle Scholar
• Tian J, Kaufman DL. The GABA and GABA-receptor system in inflammation, anti-tumor immune responses, and COVID-19. Biomedicines. 2023;11(2):254. doi:10.3390/biomedicines11020254
   PubMed Web of Science ®Google Scholar
• Zhang A, Portugal Barron D, Chen EW, Guo Z. A protein aggregation platform that distinguishes oligomers from amyloid fibrils. Analyst. 2023;148(10):2283–2294. doi:10.1039/d3an00487b
   PubMed Web of Science ®Google Scholar